Esperion Therapeutics (NASDAQ:ESPR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Esperion Therapeutics beat estimated earnings by 10.58%, reporting an EPS of $-0.93 versus an estimate of $-1.04.
Revenue was up $10.86 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.5 which was followed by a 7.11% drop in the share price the next day.
Here's a look at Esperion Therapeutics's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -2.27 | -2.79 | -1.84 | -2.52 |
| EPS Actual | -1.77 | -2.62 | -1.67 | -3.50 |
| Revenue Estimate | 14.47M | 12.85M | 42.27M | 26.12M |
| Revenue Actual | 15.40M | 14.41M | 40.66M | 7.98M |
To track all earnings releases for Esperion Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
